20 Jul 2026
Ozempic vs Wegovy in Ireland: What You Actually Need to Know
All medical information is reviewed by our clinical partners at MedicOnline.
Dr. Jahan Khan, CMO @ MedicOnline
IMC 409788
If you have been looking into weight loss treatment in Ireland, you have almost certainly come across the name Ozempic. It is one of the most searched health terms in the country. Celebrity endorsements, TikTok trends, and media coverage have made it a household name.
But here is what most of that coverage does not make clear: Ozempic is not licensed for weight loss. Not in Ireland, not in the EU, not anywhere in the world.
Ozempic and Wegovy contain the same active ingredient - semaglutide - made by the same company, Novo Nordisk. They are closely related, but they are different products with different licences, different doses, and different intended uses. Confusing the two can lead patients down the wrong path, and in some cases, toward unregulated or unsafe sources.
This guide explains the differences plainly and helps you understand which product is actually designed for weight management in Ireland.
Same Ingredient, Different Products
Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. Both are injectable, both are made by Novo Nordisk, and both reduce appetite and slow gastric emptying. That is where the similarities largely end.
Active ingredient
Ozempic: Semaglutide
Wegovy: Semaglutide
Licensed for
Ozempic: Type 2 diabetes
Wegovy: Weight management
Maximum dose
Ozempic: 1.0mg (or 2.0mg for diabetes)
Wegovy: 2.4mg
Frequency
Both: Once weekly
Approved for weight loss in Ireland
Ozempic: No
Wegovy: Yes
Clinical trial programme for weight loss
Ozempic: Not specifically studied for weight management indication
Wegovy: STEP programme (15-17% average weight loss)
Available in Ireland
Ozempic: Yes (diabetes prescription)
Wegovy: Yes (since March 2025)
The critical difference is the dose. Wegovy's maintenance dose for weight management is 2.4mg - more than double Ozempic's standard diabetes dose of 1.0mg. This higher dose is what was studied in the STEP clinical trials that demonstrated 15-17% average body weight loss. Ozempic at its lower dose was not designed or tested to deliver the same weight management outcomes.
Why Does This Confusion Exist?
Because semaglutide was originally developed for type 2 diabetes (as Ozempic), and doctors noticed that patients on it were losing significant amounts of weight. Novo Nordisk then developed a higher-dose version specifically for weight management and branded it as Wegovy.
The media ran with "Ozempic" as shorthand for the entire category because it was the name people already knew. Celebrities talked about "being on Ozempic" for weight loss. The name stuck in public conversation, even though the product most of them were actually using (or should have been using) was Wegovy.
The result is that thousands of people in Ireland search for "Ozempic for weight loss" when what they actually need is Wegovy.
The Off-Label Problem
Some doctors in Ireland have prescribed Ozempic "off-label" for weight loss - meaning for a purpose it is not officially licensed for. This practice created real problems.
In late 2022, the HSE wrote to GPs advising them against prescribing Ozempic to patients without diabetes, as off-label demand was contributing to supply shortages that affected patients with type 2 diabetes who genuinely needed the medication. The HPRA also took action against GPs and clinics that were actively advertising Ozempic for weight loss, which breaches Irish advertising regulations for prescription medicines.
The situation has improved since Wegovy became available in Ireland in March 2025, giving doctors a properly licensed alternative to prescribe for weight management. But the brand confusion persists.
Path 1
Looking for diabetes treatment?
Ozempic - prescribed by your GP or endocrinologist for type 2 diabetes.
Path 2
Looking for weight management?
Wegovy or Mounjaro - prescribed after clinical assessment for eligible patients.
What This Means If You Are Searching for Weight Loss Treatment
If you have been searching for Ozempic because you want to lose weight, what you are actually looking for is Wegovy (or Mounjaro, which works through a slightly different mechanism). These are the treatments that are:
- Specifically licensed for weight management in Ireland
- Studied in clinical trials for weight loss outcomes
- Prescribed at doses designed to be effective for weight management
- Available through legitimate, regulated pathways
Using Ozempic off-label for weight loss means you are taking a lower dose than what clinical trials showed is effective for weight management, using a product that is not monitored or supported for that purpose, and potentially contributing to supply issues for diabetes patients who depend on it.
How to Access Wegovy in Ireland the Right Way
Wegovy has been available in Ireland since March 2025 on private prescription. To access it, you need a clinical assessment by a registered doctor who will determine whether you meet the eligibility criteria:
- A BMI of 30 or above, or
- A BMI of 27 or above with at least one weight-related health condition (such as high blood pressure, prediabetes, high cholesterol, or sleep apnoea)
This is a medical decision made by a doctor after reviewing your full health profile. Not everyone will be eligible, and a prescription is never guaranteed. For a detailed guide to the eligibility process, see our post on Wegovy eligibility in Ireland.
Wegovy is not currently covered by the HSE or the Drugs Payment Scheme for weight management. Most patients access it privately, with typical monthly pharmacy costs of €170 to €250.
What About the Wegovy Pill?
The European Commission granted EU marketing authorisation for the Wegovy pill (oral semaglutide 25mg) on 15 July 2026. Novo Nordisk has said they plan to launch in EU markets in the second half of 2026. Once it reaches Irish pharmacies, it will offer a needle-free alternative for patients who prefer a daily tablet over a weekly injection.
For more on the pill, see our post on what the Wegovy pill approval means for Ireland.
It is worth noting that Rybelsus - an oral semaglutide product already available in Ireland - is licensed for type 2 diabetes only, at a much lower dose (up to 14mg). It is not a substitute for the Wegovy pill and should not be used off-label for weight loss.
How Wegovy Compares to Mounjaro
If your search for Ozempic was really a search for effective weight loss treatment, both Wegovy and Mounjaro are legitimate options. They work differently - Wegovy targets GLP-1 receptors only, while Mounjaro targets both GLP-1 and GIP receptors - and they have different cost profiles and clinical data behind them.
The SURMOUNT-5 trial compared the two head-to-head and found tirzepatide (Mounjaro) produced greater average weight loss (20.2% vs 13.7%) over 72 weeks. However, Wegovy has proven cardiovascular benefits from the SELECT trial that Mounjaro does not yet have.
The right choice depends on your individual health profile, and that is a decision for you and your doctor. For a full comparison, see our guide to Wegovy vs Mounjaro in Ireland.
The Bottom Line
Ozempic is for diabetes. Wegovy is for weight management. They share an active ingredient, but they are not interchangeable.
If you are looking for medical weight loss treatment in Ireland, the safe, effective, and properly regulated path is through Wegovy or Mounjaro, prescribed by a registered doctor after a full clinical assessment.
You can check your eligibility online in under 4 minutes. Our clinical partners at MedicOnline will review your assessment and recommend the most suitable treatment for your situation. If you are not eligible, you receive a full refund of your programme fee.
Related Reading
- Do I qualify for Wegovy in Ireland? BMI criteria, costs and eligibility explained
- Wegovy vs Mounjaro in Ireland: which weight loss injection is right for you?
- What weight loss injections are available in Ireland?
- The Wegovy pill in Ireland: when will it be available?
- Wegovy Side Effects in Ireland: A Complete Guide Before You Start
- The Wegovy Pill Has Been Approved in Europe: What This Means for Irish Patients
References
- Wilding, J. P. H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Lincoff, A. M., et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Novo Nordisk. European Commission approves Wegovy pill for weight management in the EU. 15 July 2026.
- The Irish Times. Regulator warned GPs over Ozempic advertising breaches. October 2023.
- HPRA. Promoting medicines to the public on social media.
- European Medicines Agency. Wegovy (Semaglutide): EPAR.
Related Blogs
Who Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
Read
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Read
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.
ReadWho Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.